Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Terminated 2Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Cardiotoxicity 2Breast Neoplasms 2Renal Insufficiency, Chronic 1Kidney Neoplasms 1Heart Failure 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × empagliflozin × 1 year × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT03424005 2026-03-16

Morpheus-panBC

Hoffmann-La Roche

Phase 1/2 Recruiting
792 enrolled
Breast

Breast Neoplasms

NCT06818305 2025-12-11

EmFin-Nx

Jinling Hospital, China

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Renal Insufficiency, Chronic

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting
220 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡